BioPharmSignal logoBioPharmSignal

Biotech News

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PureTech Health (PRTC)PureTech HealthCompany update

RNS Number: 2947C PureTech Health PLC 29 April 2026 29 April 2026 PureTech Health plc PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange PureTech to maintain its primary listing on the London Stock

Related news

PRTCPureTech Health2026-05-13 11:00 EST

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

PRTCPureTech Health2026-04-02 11:00 EST

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

View all latest news

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-07-13 06:00 EST

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:01 EST

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:00 EST

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-06-10 16:38 EST

Results of Annual General Meeting

PRTCPureTech Health2026-06-09 06:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

Close
17.42 USD
Market cap
424.03M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States